

May-24-2004 02:08pm From-WOODCOCK WASHBURN KURTZ MACKIEWICZ

T-833 P.021/050 F-235

DOCKET NO.: TIBO-0008 (TIP0017USA)
Application No.: 09/640,787

PATENT

EXHIBIT A

PAULA MC KENNA

PERSONAL INFORMATION

- Marital status: Married
- Nationality: Irish
- Date of birth: 23.10.1965
- Private address: Zoersel, Belgium
- E-mail: pmckenna@vrcbe.jnj.com

SUMMARY OF QUALIFICATIONS

1992 - 1994	"The Belgian Zoonosis Workgroup" Queen Astrid Military Hospital 1020 Neder-Over-Heembeek (Brussel) <i>Epidemiological studies</i>
1994 - 1996	"Janssen Research Foundation" Beerse - Belgium <i>Medical Text Writer</i>
1996 - 1997	"Janssen Research Foundation" Beerse - Belgium <i>Clinical Research Associate</i>
1997 - 1999	"Janssen Research Foundation" Beerse - Belgium <i>Associate Clinical Research Manager</i>
1999 - 2000	"Virco N.V." Generaal de Wittelaan L11B4 2800 Mechelen - Belgium <i>Project Director Business Development / Scientific Affairs Director</i>
2000 - 2001	"Virco N.V." Generaal de Wittelaan L11B4 2800 Mechelen - Belgium <i>Laboratory Director Phenotyping Unit</i>
2001 - 2002	"Tibotec-Virco NV" Generaal de Wittelaan L11B3 2800 Mechelen - Belgium <i>Director Diagnostic Lab Operations</i>
2002 -	"Virco BVBA" Generaal de Wittelaan L11B3 2800 Mechelen - Belgium

*Director Diagnostic Lab Operations***EDUCATION**

1984 - 1988	The Queens University of Belfast (QUB) <i>B.Sc. (Hons), Degree in Microbiology</i>
1988 - 1989	QUB & Institute of Tropical Medicine Antwerp - Belgium
1989 - 1992	Institute of Tropical Medicine (Erasmus Student Grant) <i>Doctor of Philosophy (Ph.D.)</i> <i>Thesis entitled : "The biology, immune response and diagnostic testing of Hantaviruses".</i>

ANNEX I**TRAINING AND DEVELOPMENT ACTIVITIES**

03/95	Bruges, Belgium	EMWA annual meeting
10/95	Baltimore, USA	AMWA annual meeting
23/11/95	JRF	Word 6.0 for beginners (PC)
Throughout 1996	JRF	GCP computer training
02/04/96	JRF	Topics in Trial Management
26/04/96	JRF	CIMS, CIMS Field, CIMS Access
09/05/96	JRF, Hilton Hotel Antwerp	Clinical Lab Testing
11-13/09/96	JRF	Project Plans
Throughout 1996	JRF	"Ken Uw Onderneming"
24/01/97	JRF	Excel 5.0 for beginners
30/01/97	JRF	Powerpoint 4.0
17/02/97	JRF	GCP Biological Samples

1-5/06/97	Rhodes	EACCI annual Congress
10/06/97	JRF, Hilton Hotel Antwerp	Project Management for Teams
10/06/97	JRF	Electronic TMF (Trial Master File)
19/08/97	JRF	Windows 95 (van Windows 3.11 naar Windows 95)
10/97 -01/98	KUL, Leuven	Dermatology course (Prof. Degreef)
25/11/97	JRF	CIMS 3.1 HO, CIMS/ACCESS
29/11/97	UIA, Antwerp	Skin & Immunologie
24-25/02/98	London	Drug Information Association Workshop
23/02/98	JRF	TCM training
11, 30, 31/03/98	Ontmoetingscentrum, Turnhout	Presentation techniques
18-20/05/98	Paris	8 th Int. Congress of Pediatric Dermatology
10/06/98	JRF	Training, IB & amendments & SAE reporting
27-28/08/98	JRF	Statistical issues in the design of clinical trials
22-24/03/99	De Residentie, Lichtaart	Advanced GCP course
Regular basis	JRF	SOP's training
Regular basis	JRF	GCP workshop CRA's
Regular basis	JRF	CIMS Field Follow-up
Regular basis	JRF	Monitor Meetings
Regular basis	JRF	Clinical sub-team meetings
Regular basis	JRF	Development Project Team Meetings
23/07/99	Virco N.V.	Structure based drug design molecular modelling

13/09/99	Rome, Italy	The Rome State of the Art Conference on the Treatment of HIV infection
30/01/00	San Francisco, USA	7 th Conference on Retroviruses and Opportunistic Infections
25/02/00	Frankfurt, Germany	2 nd Frankfurt Symposium on the Clinical Implications of HIV Drug Resistance
17-20/Sept-2000	Toronto, Canada	40 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Sept-2000	Gothenburg, Sweden	3 rd Workshop Proficiency testing in analytical chemistry, microbiology and laboratory medicine
Oct-2000	Amsterdam, the Netherlands	European Biosafety Association
25 Feb. 2001	Frankfurt, Germany	3 rd European Symposium on the Clinical Implications of HIV Drug Resistance
April-2002	Antwerp, Belgium	DIA Workshop: Re-engineering Clinical Trial Logistics
October 2003	Warsaw, Poland	EACS
October 2003	Antwerp, Belgium	Finance for non-financial Managers
8-11 Feb 2004	San Francisco, USA	11 th Conference on Retroviruses and Opportunistic Infections.

PROFESSIONAL MEMBERSHIPS AND ACTIVITIES

Member of the European Writers Association
(EMWA) 1994 - 1996

ANNEX II

ABSTRACTS

1. *Seroepidemiological study of Lyme and tick-borne encephalitis (TBE) : immune status of American troops in southern Germany.*
J. Clement, H. Leirs, P. Mc Kenna, V. Armour, D. Ward, J. Groen, A. Osterhaus, C. Kunz.
Second European Symposium on Lyme Borreliosis. St. George's Hospital Medical School, University of London, U.K. May 19-20, 1993.
2. *Icterus and ARF : Leptospirosis (LSP) or Hantavirus Disease (HVD)?*
J. Clement, P. Mc Kenna, C. Mc Caughey, G. Neild, S. Hindrichsen, G. Van der Groen.
International Symposium on Acute Renal Failure. Satellite Symposium of the XIIth International Congress of Nephrology. Jeruzalem, Israël, June 13-18, 1993. Halkidiki, Greece, June 20 -23, 1993.
3. *Leptospirose (LSP) ou néphropathie à Hantavirus (NHV) ?*
J. Clement, P. Mc Kenna, H. Leirs, G. Van der Groen.
Réunion annuelle de la Société de Néphrologie. Brussels, October 20-22, 1993.
4. *Leptospirosis (LSP) or rat-transmitted hantavirus (HV) nephropathy ?*
J. Clement, P. Mc Kenna, H. Leirs, G. Van der Groen.
First Scientific Meeting of the Belgian Society of Nephrology. Liege, Belgium, December 4, 1993.
5. *Risk of exposure to Tick-borne encephalitis (TBE) and Lyme disease in Southern Germany.*
J. Clement, H. Leirs, P. Mc Kenna, V. Armour, D. Ward, J. Groen, A. Osterhaus, C. Kunz
1ste Wetenschappelijke vergadering. Bruges, Belgium, December 12, 1993.
6. *The wild rat as vector for acute hantavirus (HV) nephropathy.*
J. Clement, P. Mc Kenna, G. Van der Groen, S. Hindrichsen.
Dutch Society of Nephrology, 49th Scientific Meeting. Amsterdam, The Netherlands, February 19, 1994.
7. *Hantavirus nephropathy (HVN) : Not just an arcane zoonosis.*
J. Clement, P. Colson, Ph. Damoiseaux, P. Mc Kenna, J. Coeck, J. Neyts, H. Leirs, R. Verhagen.
Dutch Society of Nephrology, 50th Scientific Meeting. Maastricht, The Netherlands, April 16, 1994.
8. *Defaillance Multiviscerale causee par un Hantavirus en Europe Occidentale.*
P. Colson, Ph. Lefebvre, C. Lescot, C.H. Chimay, J. Clement, P. Mc Kenna.
Réunion Annuelle des Communications Libres. U.C.L. Woluwé, Belgium, April 21, 1994.

9. *Nephropathia Epidemica (NE) complicated by adult respiratory distress syndrome (ARDS) and acute Renal Failure (ARF) : A novel Pneumo-renal Syndrome.*
P. Colson, Ph. Lefebvre, C. Lescot, J. Clement, P. Mc Kenna, J. Neyts, J. Coeck.
Joint Meeting of the Belgian Societies of Internal Medicine & Nephrology. Château de Limelette, Wavre, Belgium, May 7, 1994.
10. *Canine Lyme Disease in Belgium.*
P. Mc Kenna, J. Clement, T. Van den Bogaard, G. Bigaignon.
VI International Conference on Lyme Borreliosis. Bologna, Italy, June 19-22, 1994.
11. *1993 Hantavirus (HV) Epidemic in the Ardennes.*
J. Clement, P. Colson, Ph. Damoiseaux, P. Mc Kenna, J. Coeck, J. Neyts, H. Leirs, R. Verhagen.
XXXIst Congress of the European Dialysis & Transplant Association, European Renal Association, Vienna, Austria, July 3-6, 1994.
12. *Hantavirus Pulmonary Syndrome (HPS) as a complication during a 1993 Nephropathia Epidemica (NE) outbreak in Belgium.*
J. Clement, P. Mc Kenna, P. Colson, P. Lefebvre, C. Lescot, J. Neyts, J. Coeck.
43rd Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH). Cincinnati, Ohio, U.S.A., November 13-17, 1994.
13. *Epidemiologische en klinische kenmerken van een Hantavirus (HV) epidemie tussen Sambre en Maas in 1993.*
J. Clement, P. Colson, Ph. Damoiseaux, P. Mc Kenna, P. Heyman, J. Coeck, J. Neyts.
3de Wetenschappelijke Vergadering. Belgische Vereniging voor Infectiologie en Klinische Microbiologie at AZ-VUB, Belgium. December 15, 1994.
14. *Total Serum Cholesterol (CHOL), HDL Cholesterol and Triglycerides (TG) as predictors of Clinical Severity in Hantavirus (HTV) Infection.*
J. Clement, P. Colson, P. Mc Kenna, P. Heyman.
Belgische Vereniging voor Nefrologie, Mons (Belgium), May 20th 1995.
15. *Hantavirus Pulmonary Syndrome (HPS) as a complication during a 1993 Nephropathia epidemica (NE) outbreak in Belgium.*
J. Clement, P. Mc Kenna, P. Colson, P. Lefebvre, C. Lescot.
3rd International Conference on HFRS and Hantaviruses.
Helsinki, Finland, May 31 - June 3, 1995.
16. *Total serum cholesterol (CHOL), HDL cholesterol and triglycerides (TG) as predictors of clinical severity in Belgian cases of Nephropathia epidemica (NE).*
J. Clement, P. Colson, P. Mc Kenna, P. Heyman
3rd International Conference on HFRS and Hantaviruses.
Helsinki, Finland, May 31 - June 3, 1995.

17. *Total Serum (s.) Cholesterol (CHOL), HDL Cholesterol and Triglycerides (TG) as predictors of Clinical Severity in Hantavirus (HTV) Infection.*
J. Clement, P. Colson, P. Mc Kenna, P. Heyman.
Belgische Vereniging voor Klinische Biologie. National Symposium
CHU, Sart-Tilman, Liege, October 14, 1995.
18. *Total Serum (s.) Cholesterol (CHOL), HDL Cholesterol and Triglycerides (TG) as predictors of Clinical Severity in Hantavirus (HTV) Infection.*
J. Clement, P. Colson, P. Mc Kenna, P. Heyman
44th Annual Meeting of the American Society of Tropical Medicine and
Hygiene (ASTMH), San Antonio, Texas 18-21 November 1995.
19. *Een case-control studie naar risico's voor het oplopen van Hantavirus-infecties in de streek van Chimay.*
J. Clement, P. Mc Kenna, S. Ghos, I. Thomas, F. Van Loock, P. Colson.
Belgische Vereniging voor Interne Geneeskunde. Brussels, Belgium,
January 20, 1996.
20. *Epidemiological characteristics of a 'Nephropathia epidemica' (NE) outbreak in South-West Germany.*
J. Clement, P. Mc Kenna, A. Lefevre, P. Heyman, P. Underwood, D.
Ward, J. Quan, J. LeDuc.
Renal Association with the Dutch Society for Nephrology, Oxford,
March 27-29, 1996.
21. *A Cluster of Hantavirus acute renal failure (ARF) during Military manoeuvres in SW-Germany : a lesson for Bosnia.*
J. Clement, P. Mc Kenna, P. Heyman, P. Underwood, D. Ward, J. LeDuc.
Belgische Vereniging voor Nefrologie. Diepenbeek, Belgium, April 27,
1996.
22. *Serum (S) Lipids as predictors of Clinical Severity in Nephropathia Epidemica (NE), the European form of Hantavirus (HTV) Nephropathy.*
J. Clement, P. Mc Kenna, P. Heyman, P. Colson.
European Renal Association. European Dialysis and Transplant
Association, Annual Congress, Amsterdam, The Netherlands, June 18-
21, 1996.
23. *The Hantaviruses (HTV) of Europe : From the bedside to the Bench.*
J. Clement, P. Heyman, P. Mc Kenna, P. Colson.
1st International Conference on Emerging Zoonoses. November 24-28,
1996.
24. *Hantavirus (HTV) Rodent Epizootology in Belgium, Germany and the Netherlands.*
J. Clement, A. Lefevre, P. Mc Kenna.
1st International Conference on Emerging Zoonoses. November 24-28,
1996.

25. *Sero-Epidemiological Study of Lyme and Tick-borne encephalitis (TBE) Immune Status of US Troops in South-Germany.*
J. Clement, H. Leirs, P. Mc Kenna, V. Armour, D. Ward, J. Groen, A. Osterhaus, C. Kunz.
Annals of the Rheumatic Diseases.
26. *Wild Rats: A vector of Hantavirus Disease (HVD) in N. Ireland?*
P. Mc Kenna, J. Clement, C. Mc Caughey, P. Coyle.
27. *Worldwide Evaluation of Genotypic Resistance Analysis Using Clinical HIV-1 Isolates with Complex Drug Resistance Profiles.* M. De Wit, M. Peeters, P. Mc Kenna, K. Hertogs. 8th Conference on Retroviruses and Opportunistic Infections, 4-8 February 2001, Chicago, USA.
28. *HIV RNA from gastrointestinal mucosa shows similar reverse transcriptase and protease mutations and phenotypic HIV-1 drug resistance as plasma-derived HIV.* J. Vingerhoets, MA Poles, J. Elliott, R. Harrigan, B. Larder, P. Mc Kenna, K. Hertogs and PA Anton. 5th International Workshop on HIV Drug Resistance & Treatment Strategies, 4-8 June 2001, Scottsdale, Arizona.
29. *The fusion inhibitors T-20 and T-1249 demonstrate potent in vitro antiviral activity against clade B HIV-1 isolates resistant to reverse transcriptase and protease inhibitors and non-B clades.* P. Sista, T. Melby, U. Dhingra, N. Cammack, P. Mc Kenna, P. Dehertogh and T. Matthews. 5th International Workshop on HIV Drug Resistance & Treatment Strategies, 4-8 June 2001, Scottsdale, Arizona.
30. *Characteristics of tenofovir phenotypic susceptibility.* MD Miller, P. Mc Kenna, BA Larder and PR Harrigan. 5th International Workshop on HIV Drug Resistance & Treatment Strategies, 4-8 June 2001, Scottsdale, Arizona.
31. *BCH-10618, a new hetero substituted nucleoside analogue against HIV-1 infection.* Z. Gu, N. Nguyen-Ba, C. Ren, JM De Muys, B. Allard, MA Wainberg, P. Mc Kenna, DL Taylor and RC Bethell. 5th International Workshop on HIV Drug Resistance & Treatment Strategies, 4-8 June 2001, Scottsdale, Arizona.
32. *HIV RNA from gastrointestinal mucosa shows similar RT and protease mutations and phenotypic HIV-1 drug resistance as plasma-derived HIV.* J. Vingerhoets, M.A. Poles, J. Elliott, R. Harrigan, B. Larder, P. Mckenna, K. Hertogs, P.A. Anton. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 16-19 December 2001, Chicago, Illinois, USA.
33. *Phenotypic analysis of Tenofovir susceptibility among 5000 clinical HIV-1 isolates.* P.R. Harrigan, P. Mckenna, B.A. Larder, M.D. Miller. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 16-19 December 2001, Chicago, Illinois, USA

34. *New hetero-substituted nucleoside analogue, is an effective inhibitor of drug-resistant HIV-1.* R.C.Bethell, B.Allard, J.M.De Muys, Z.Gu, N.Guyen-Ba, C.Ren, M.A.Wainberg, P.Mckenna and D.L.Taylor. 9th Conference on Retroviruses and Opportunistic Infections, 24-28 February 2002, Seattle, WA, USA
35. *Randomized comparison of 2 resistance test platforms: Genotype and VirtualPhenotype.* C. Workman, G. Hales and P.Mckenna. 9th Conference on Retroviruses and Opportunistic Infections, 24-28 February 2002, Seattle, WA, USA
36. *Duodenal HIV-1 RNA load is increased in both HIV patients with an opportunistic intestinal pathogen or pathogen negative diarrhoea.* P. Hayes, D. Datta, Y. Miao, J. Vingerhoets, E. Fordel, P. Mc Kenna, A. Poznial, B. Gazzard. XIVth International Aids Conference Barcelona July 7-12, 2002.
37. *Trends in genotypic and phenotypic resistance among clinical samples submitted for routine HIV resistance analysis.* L. Bacheler, H. Vermeiren, P. Mc Kenna, M. Van Houtte and P. Lecocq. XII International HIV Drug Resistance workshop June 10-14, 2003 Cabo des Sol, Los Cabos, Mexico.
38. *Extensive phenotypic resistance and cross resistance among recent clinical samples submitted for routine HIV resistance analysis.* L. Bacheler, H. Vermeiren, P. Mc Kenna, M. Van Houtte, P. Lecocq. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, July 13-16, 2003.
39. *Phenotypic Resistance and Prevalence of Specific Nucleoside Analog Mutation Combinations (NAMs) in Reverse Transcriptase in a Dataset of Recent HIV-1 Clinical Isolates.* M. Van Houtte, P. Lecocq, P. Mc Kenna, L. Bacheler. 43rd Annual ICAAC Chicago September 14-17, 2003
40. *Trends in Genotypic and Phenotypic HIV-1 Drug Resistance among Recent Clinical Samples Submitted for Resistance Testing.* L. Bacheler, H. Vermeiren, P. Mc Kenna, M. Van Houtte, P. Lecocq. 43rd Annual ICAAC Chicago September 14-17, 2003
41. *Mutational Patterns and Quantitative Phenotypic resistance profile associated with alleles Q/E, Na dn R at position 219 in reverse transcriptase in a large dataset of recent HIV-1 clinical isolates.* M. Van Houtte, P. Mc Kenna, P. Lecocq, L. Bacheler. 9th European Aids Conference (EACS) Warsaw, Poland. October 25-29, 2003.
42. *Unusual mutations at HIV-1 RT codon 103 cause NNRTI resistance.* Harrigan P.R., Wynhoven B., Montaner J., Pattery T., Mc Kenna P., Vingerhoets J., Bacheler L. 9th European Aids Conference (EACS) Warsaw, Poland. October 25-29, 2003.

43. *Antiviral Activity of TMC125 against a Panel of Site-directed Mutants Encompassing Mutations Observed in vitro and in vivo.* J. Vingerhoets, I. De Baere, H. Azijn, T. Van den Bulcke, P. Mc Kenna, T. Pattery, R. Pauwels, M-P. De Bethune. 11th CROI, San Francisco USA, February 8-11, 2004.

PUBLICATIONS

1. *Sero-epidemiologisch onderzoek naar de verspreiding van Lyme borreliose bij paarden, honden en runderen.*
G. Lenaers, H. Leirs, P. Mc Kenna, J. Clement
Ann. Med. Milit. Belg. 1992;6 (2) : 61-63
2. *Eradication of Hantavirus infection among laboratory rats by application of caesarian section and a foster mother technique.*
P. Mc Kenna, G. Van der Groen, G. Hoofd, C. Beelaert, H. Leirs, R. Verhagen, J.P. Kints, F. Cormont, F. Nisol, H. Bazin
The British Society for the Study of Infection. Journal of Infection (1992) 25, 181-190
3. *Hantavirus Infection in Brazilian patients from Recife with suspected Leptospirosis.*
S. Hindrichsen, A. Medeiros de Andrade, J. Clement, H. Leirs, P. Mc Kenna, P. Matthys, G.H. Neild
The Lancet - 2.01.1993 - Vol. 341 - N°8836 - page 50
4. *Serological Evidence of Hantavirus Disease in Northern Ireland.*
P. Mc Kenna, J. Clement, P. Matthys, P.V. Coyle, C. McCaughey
Journal of Medical Virology 43:33-38 (1994), printed by Wiley-Liss Inc.
5. *Parallelism between Lyme and Tick-Borne Encephalitis (TBE) Sero-Epidemiology following occupational exposure in S. Germany.*
J. Clement, H. Leirs, P. Mc Kenna, V. Armour, D. Ward, J. Groen, A. Osterhaus, C. Kunz
Lyme Borreliosis, Edited by J.S. Axford and D.H.E. Rees, Plenum Press, New York, 1994
6. *Hantavirus Epidemic in Europe, 1993.*
J. Clement, P. Mc Kenna, P. Colson, Ph. Damoiseaux, C. Penalba, P. Halin, D. Lombart
The Lancet - 08.01.1994 - Vol. 343 - page 114.
7. *Risk of Concomitant Exposure of Tick-Borne Encephalitis (TBE) and Borrelia burgdorferi (Bv) in 2-sample study.*
J. Clement, P. Mc Kenna, H. Leirs, C. Kunz
Acta Clinica Belgica. Volume 49 - N°2 -1994.
8. *1993 Hantavirus (HV) epidemic in the Ardennes.*
J. Clement, P. Colson, Ph. Damoiseaux, P. Mc Kenna, J. Coeck, J. Neyts, H. Leirs, R. Verhagen
Official Publication of the European Dialysis and Transplant Association - European Renal Association. Oxford University Press. Volume 9 - N°7 - 1994.
9. *Hantaviruse en Belgique.*
J. Clement, P. Colson, I. Thomas, P. Mc Kenna, J. Neyts, J. Coeck, G. Van der Groen, H. Leirs, R. Verhagen.

Ann. Med. Vet., 1994, 138, 257-262.

10. *Rat-transmitted Hantavirus disease in Sarajevo.*
J. Clement, P. Mc Kenna, T. Avsic-Zupanc, C.R. Skinner
The Lancet - 09.07.1994 - Vol. 344 - N° 8915 - page 131.
11. *Hantavirus Pulmonary Syndrome in New England and Europe.*
J. Clement, P. Colson, P. Mc Kenna.
New England Journal of Medicine. 25.08.1994.
12. *Hantavirus Infections in Rodents.*
J. Clement, P. Mc Kenna, H. Leirs, R. Verhagen, A. Lefevre, G. Song, E. Tkachenko, G. Van der Groen.
Reprinted from : Virus Infections of Vertebrates, 5. "Virus Infections of Rodents and Lagomorphs". Elsevier Science B.V. 1994.
13. *Hantaviruses.*
Zoonoses Textbook (Oxford University Press).
14. *Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against Tick-Borne encephalitis.*
P. Mc Kenna
Journal of Medical Virology. Vienna, 21.08.1995.
15. *Canine Lyme disease in Belgium.*
P. Mc Kenna, J. Clement, D. Van Dijck, M. Lauwerys, D. Carey, T. Van den Bogaard, G. Bigaignon.
The Veterinary Record (1995) 136, 244-247.
16. *Epidemie d'Hanta Virose dans l'entre-Sambre-et-Meuse.*
P. Colson, Ph. Damoiseaux, J. Brisbois, F. Duvivier, P. Levecque, J.M. Roger, D-J. Bouilliez, P. Mc Kenna, J. Clement.
Acta Clinica Belgica, 50-4, 1995.
17. *Epidemiology and Laboratory Diagnosis of Hantavirus (HTV) Infections.*
J. Clement, P. Mc Kenna, J. Groen, A. Osterhaus, P. Colson, T. Vervoort, G. Van der Groen, H.W. Lee.
Acta Clinica Belgica, 50-1, 1995.
18. *Hantavirus (HTV) Infecties in België : van muizen en mensen. Hantavirus (HTV) Infections in Belgium : of mice and men.*
J. Clement, P. Colson, P. Heyman, P. Matthys, J. Neyts, J. Coeck. P. Mc Kenna
NT Geneeskunde - update 23.05.1995.
19. *Differential Antiviral Activity of Derivatized Dextrans.*
J. Neyts, D. Reymen, D. Letourneur, J. Jozefonvicz, D. Schols, J. Este, G. Andrei, P. Mc Kenna, M. Witvrouw, S. Ikeda, J. Clement, E. De Clercq.
Biochemical Pharmacology. Vol. 50 - N° 6 - page 743-751, 1995.

20. *The Hanta Virus (HTV) of Europe : from the bedside to the bench.*
J. Clement, P. Heyman, **P. Mc Kenna**, P. Colson, T. Avsic-Zupanc
Journal of the Emerging Infectious Diseases (EID) 1996.
21. *Correlation between ELISA, Hemagglutination Inhibition, and Neutralization Tests after Vaccination Against Tick-Borne Encephalitis.*
H. Holzmann, M. Kundi, K. Stiasny, J. Clement, **P. Mc Kenna**, C. Kunz, F.X. Heinz.
Journal of Medical Virology 48:102-107 (1996)
22. *The Hantaviruses of Europe . from the bedside to the Bench.*
J. Clement, P. Heyman, **P. Mc Kenna**, P. Colson, T. Avsic-Zupanc
Reprinted from Emerging Infectious Diseases. Vol. 3 - N°2, 205-211,
April-June 1997.
23. *Evaluation of the local tolerance, systemic absorption and safety of 0.1 ml of a 0.125% ointment of R126521 or placebo after single topical application on intact and abraded skin and repeated application on intact skin of healthy volunteers.* J. Leempoels, F. De Ridder, H. De Smedt, A. De Dier, **P. Mc Kenna**, I. Hallemans. Synoptic clinical research report on R126521 BEL-1, December 1999 (cover only)
24. *Comparison of the anti-inflammatory effect, systemic absorption, local tolerance and safety of R126521 ointment and R126521 solution with their respective placebo after repeated topical application on the skin of atopic dermatitis subjects.* H. Degreef, L. Meuleners, C. Vertommen, A. De Dier, **P. Mc Kenna**, A. De Deene, P. De Doncker - Synoptic clinical research report on R126521 BEL-2, April 2000.
25. *Itraconazole in the treatment of dermatophytosis. A multicenter evaluation between different treatment schedules.* J. Decroix, A. De Dier, **P. Mc Kenna**, P. De Doncker - Synoptic clinical research report on R51211 - December 1998.
26. *An open trial on the efficacy, pharmacokinetics, laboratory safety and tolerability of R91767 in HIV-positive patients.* S. Staszewski, J. De Cree, V. Miller, **P. Mc Kenna**, K. Groen, M. De Branbender, M. Moeremans, K. Andries, W. Verbiest, P. Stoffels - Clinical research report on R91767 GER-1, January 1996.
27. *A third-party-blinded, placebo-controlled evaluation of the anti-inflammatory effect, systemic absorption, clinical laboratory safety and tolerability of repeated dermal applications of 0.05% R115500 solution and 0.1% betamethasone valerate cream in three human models of cutaneous inflammation in healthy adult subjects.* R. Marks, A. De Dier, **P. Mc Kenna**, H. De Smedt - Synoptic clinical research report on R115500 GBR-1, May 1998.
28. *A double-blind, randomized, placebo-controlled trial to investigate the effect of a once daily oral administration of R089674 0.05, 0.1, 1 or 2 mg for 1 week on the clinical response to nasal allergen challenge in 60 atopic volunteers.* C. Bachert,

- M. Tajerbashi, R. Luehning, A. De Dier, P. Mc Kenna, M. Peeters, I. Van Hove - Synoptic clinical research report on R89674 GER-1, March 1998.
29. *A double-blind, randomised, placebo-controlled trial to investigate the efficacy and safety of a 2-week once daily oral administration of R089674 0.1 mg, 0.5 mg, 1 mg or 2 mg versus placebo in subjects with seasonal allergic rhinitis of rhinoconjunctivitis.* R. Dahl, G. Aasand, G. Persson, L. Guldback, B. Varaas, L. Oveblychert, A. De Dier, M. Peeters, I. Van Hove, P. Mc Kenna, et al. - Synoptic clinical research report on R89674 INT-1, March 1998.
30. *A double-blind, randomised, controlled trial to investigate the efficacy and the safety of a 2-week administration of 1 mg R089674, 10 mg Cetirizine, or placebo in atopic dermatitis.* C. Adam, A. De Dier, P. Mc Kenna, M. Peeters, I. Van Hove - Synoptic clinical research report on R89674 BEL-4, March 1998.
31. *Comparison of the efficacy and tolerability of Nebivolol combined with Nitrendipine and placebo combined with Nitrendipine in the treatment of hypertension resistant to Nitrendipine.* A. Simon, C. Vertommen, P. Mc Kenna, L. Van Nueten, A. Dupont - Clinical research report on R67555 NEB-FRA-6, June 1998.
32. *Evaluation of safety, tolerability and efficacy of R093877 (enterokinetic) given intravenously in patients undergoing major abdominal surgery.* U. Hildebrandt, P. Mc Kenna, L. Cornwell, R. Kerstens, G. Van 't Klooster, L. Vandeplasseche - Clinical research report on R93877 PRU-GER-1, June 1996.
33. *Investigation of the efficacy and tolerability of topical liarozole (R75251) in the treatment of moderate plaque psoriasis. A Randomized, double-blind, vehicle-controlled, dose-finding study.* J.M. Lachapelle, W. Verbiest, P. Mc Kenna, A. Heremans - Synoptic clinical research report on R75251 LIA-INT-9, April 1996.
34. *Systemic absorption and tolerability of loviride plus chlorhexidine after daily intravaginal administration for two weeks.* M. Temmerman, P. Mc Kenna, W. Verbiest, P. Stoffels - Clinical research report on R89439 LOV-BEL-6, February 1996.
35. *Oxatomide 3% emulsion in the treatment of essential and/or senile pruritus.* K. Meyer, P. De Doncker, P. Mc Kenna, A. Heremans - Synoptic clinical research report on R35443 OXA-INT-2, December 1995.
36. *Comparison of two dosing regimens of cisapride (10 mg QID and 20 mg BID) in the treatment of reflux oesophagitis. An international multicentre trial.* W. Peterz, K. Schuetze, H. Wurzer, L. Van Waes, M.A. Bigard, G. Bedogni, M. Bianco, R. Corinaldesi, J. Hinojosa, J. Ponce, L. Rodrigo, G. Anthonijs, P. Mc Kenna, M. Verlinden - Clinical research report on R51619 CIS-INT-14, October 1996.
37. *The effect of Liarozole (R75251) in the treatment of advanced malignant melanoma.* A.T. Van Ooserom, P. De Porre, P. Mc Kenna, J. Bruynseels -

Synoptic clinical research report on R75251 LIA-BEL-7, December 1995.

38. *Randomised, double-blind trial of the efficacy and tolerability of itraconazole 200 mg compared with terbinafine 250 mg in the treatment of tinea corporis/cruris.* J. Decroix, P. De Doncker, P. Mc Kenna, M. Cortens, J. Snoecks, A. Heremans – Clinical research report on R51211 ITR-INT-18, October 1995.
39. *Pharmacokinetics and safety of R093777 in healthy volunteers after a single oral dose of 10 mg and after a 10 mg twice-daily regimen. Part 1: safety.* L. Van Bortel, P. Mc Kenna, M. De Pauw, I. Van De Velde, M. Verlinden – Clinical research report on R93777 BEL-8, March 1996.
40. *A double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy of oral ridogrel in the treatment of acute ulcerative colitis.* J. Wright, G. Schenowitz, G. Adler, H. Schneider, K.J. Taylor, P. Mc Kenna, M. Verlinden – Clinical research report on R68070 RID-INT-2, May 1995.
41. *Effect of loperamide oxide (1 mg tablets) in the treatment of acute diarrhoea in children (6-12 years). An open clinical study.* B. Van Den Eynden, P. Mc Kenna, L. Vandeplasseche, M. Verlinden, L. Lauwers – Clinical research report on R58425 LOX-BEL-18, January 1996.
42. *Comparative oral bioavailability of a R93877 capsule and a R93877 solution and the food effect on the oral bioavailability of the R93877 capsule in healthy volunteers. Part II: tolerability and laboratory safety.* L. Van Bortel, L. Vandeplasseche, P. Mc Kenna, M. Verlinden – Clinical research report on R93877 PRU-BEL-4, June 1995.
43. *Ridogrel in the treatment of ulcerative colitis. Part II: maintenance phase with oral ridogrel after healing with rectal ridogrel or prednisolone.* F. Huble, M. Van Outryve, M. Devos, P. Mc Kenna, K. Taylor, M. Verlinden – Clinical research report on R68070 RID-BEL-26, May 1995.
44. *A determination of the comparative bioavailability of ridogrel when administered orally and rectally to patients with ulcerative colitis, part II: tolerability and safety.* G.N.J. Tytgat, H. Van Dullemen, S. Tytgat, P. Fockens, M. Verlinden, K. Taylor, P. Mc Kenna – Clinical research report on R68070 RID-NED-3, April 1995.
45. *Effect of loperamide oxide in comparison to loperamide and placebo in patients with Crohn's disease.* G. Stacher, A. Wigerinck, P. Mc Kenna, M. Verlinden – Synoptic clinical research report on R58425 LOX-AUT-3, October 1995.
46. *Evaluation of loperamide oxide (R058425) in the treatment of patients with radiation-induced diarrhoea.* E. Beubler, P. Mc Kenna, L. Vandeplasseche, M. Verlinden, L. Lauwers.
47. *Effect of loperamide oxide (1 mg tablets) in the treatment of acute diarrhoea in Elderly. A double-blind, placebo controlled study.* W. Spaepen, P. Mc Kenna,

L. Vandeplasseche, M. Verlinden - Clinical research report on R58425 LOX-BEL-4, September 1995.

48. *Efficacy of loperamide oxide (0.5 mg, 1.0 mg and 2.0 mg) in acute diarrhoea in adults. A double-blind, randomized, dose-effect comparison with loperamide (2 mg tablets) and placebo.* H. Ruppin, P. Mc Kenna, L. Vandeplasseche, M. Verlinden, L. Lauwers - Clinical research report on R58425 LOX-GER-1, January 1996.
49. *Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.* P.R.Harrigan, M.D.Miller, P. McKenna, Z.L.Brumme and B.A.Larder. - Antimicrob Agents Chemother 46, 1067-72 (2002). 11
50. *A mutation in the 3' Region of the human immunodeficiency virus Type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.* P.R. Harrigan, M. Salim, D.K.Stammers; B.Wynhoven, Z.L.Brumme, P.McKenna, B.Larder and S.D.Kemp. - Journal of Virology, 6836-6840 (2002).